• 1. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 4. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Methyl 5-bromo-1H-imidazo[4,5-b]pyridine-2-carboxylate (CAS No. 1257852-22-4): A Key Intermediate in Modern Pharmaceutical Research

Methyl 5-bromo-1H-imidazo[4,5-b]pyridine-2-carboxylate, identified by its CAS number 1257852-22-4, is a highly versatile and significant compound in the realm of pharmaceutical chemistry. This heterocyclic derivative has garnered considerable attention due to its utility as a crucial intermediate in the synthesis of various biologically active molecules. The structural framework of this compound, featuring a fused imidazole and pyridine ring system, coupled with the presence of a bromine substituent and a carboxylate ester group, makes it an invaluable building block for medicinal chemists.

The< strong>imido[4,5-b]pyridine core is a privileged scaffold in drug discovery, known for its ability to interact with biological targets in multiple ways. The bromine atom at the 5-position enhances the reactivity of the molecule, allowing for further functionalization through cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These transformations are pivotal in constructing complex molecular architectures, which are often required for achieving high affinity and selectivity in drug candidates.

The< strong>carboxylate ester functionality provides an additional handle for chemical manipulation. It can be readily converted into other pharmacophoric groups, such as amides or acids, through hydrolysis or transesterification reactions. This adaptability makes Methyl 5-bromo-1H-imidazo[4,5-b]pyridine-2-carboxylate a preferred choice for libraries of compounds designed for high-throughput screening (HTS) and fragment-based drug design (FBDD).

In recent years, there has been a surge in research focused on developing novel treatments for cancer and infectious diseases. The< strong>imidazo[4,5-b]pyridine scaffold has been extensively explored for its potential as an inhibitor of kinases and other enzymes involved in tumor growth and viral replication. For instance, derivatives of this scaffold have shown promise in targeting Bruton's tyrosine kinase (BTK), a key enzyme in B-cell signaling pathways, making them relevant in the treatment of autoimmune disorders like rheumatoid arthritis.

Moreover, the< strong>brominated imidazo[4,5-b]pyridines have been investigated for their antiviral properties. Studies have demonstrated that certain brominated derivatives exhibit inhibitory activity against viruses such as HIV by interfering with viral protease activity or integrase function. The carboxylate ester moiety allows for modifications that can fine-tune the pharmacokinetic properties of these antiviral agents, enhancing their efficacy and reducing side effects.

The synthesis of Methyl 5-bromo-1H-imidazo[4,5-b]pyridine-2-carboxylate typically involves multi-step organic transformations starting from readily available precursors. One common approach involves the condensation of β-ketoesters with amidines or hydrazides to form the imidazo[4,5-b]pyridine core. Subsequent bromination at the 5-position can be achieved using brominating agents such as N-bromosuccinimide (NBS). The introduction of the carboxylate ester group is usually accomplished through esterification reactions using carboxylic acids or acid chlorides.

The compound's stability under various reaction conditions makes it a reliable reagent in synthetic chemistry. It can be stored under inert atmospheres at ambient temperature without significant degradation, ensuring its availability for multiple synthetic applications. Additionally, its solubility profile allows for easy handling and purification via techniques such as column chromatography or recrystallization.

The growing interest in< strong>Methyl 5-bromo-1H-imidazo[4,5-b]pyridine-2-carboxylate extends beyond academic research into industrial applications. Pharmaceutical companies are increasingly leveraging this intermediate to develop novel drug candidates with improved pharmacological profiles. The ability to rapidly modify its structure through well-established synthetic methodologies enables rapid iteration in drug discovery programs.

In conclusion, Methyl 5-bromo-1H-imidazo[4,5-b]pyridine-2-carboxylate (CAS No. 1257852-22-4) is a cornerstone compound in modern pharmaceutical research. Its unique structural features and reactivity make it an indispensable tool for medicinal chemists seeking to develop innovative therapeutic agents. As research continues to uncover new biological targets and synthetic strategies, this compound will undoubtedly remain at the forefront of drug discovery efforts.

• 1252572-34-1(methyl 6-bromo-1H-imidazo[4,5-b]pyridine-2-carboxylate)
• 2090149-14-5(ethyl 5-bromoimidazo[1,5-a]pyridine-3-carboxylate)
• 1257849-18-5(5-Bromo-1H-imidazo[4,5-b]pyridine-2-carboxylic acid)
• 97640-17-0(methyl 3H-imidazo[4,5-b]pyridine-2-carboxylate)
• 93129-54-5(ethyl 3H-imidazo[4,5-b]pyridine-2-carboxylate)
• 1257851-84-5(Ethyl 5-bromo-1H-imidazo[4,5-b]pyridine-2-carboxylate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)